CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Tenofovir 300Mg Oral Tablet +1 moredrug
Likely dose
Tenofovir 300Mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03917420
NCT03917420Phase 1Completed

Quantification of Estradiol's Impact on Nucleotides in Different Cellular Populations of the Lower Gastrointestinal Tract

University of North Carolina, Chapel Hill·interventional·Posted Apr 17, 2019·Updated Apr 12, 2023

In Brief

A Phase 1 clinical trial evaluating Tenofovir 300Mg Oral Tablet and Emtricitabine 200 MG for HIV/AIDS. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Purpose: To Assess the impact of high and low in vivo estradiol exposure on PrEP (Pre-exposure prophylaxis) nucleotide concentrations in different cellular populations of the lower GI (gastrointestinal) tract and to quantify the relationship between estradiol, progesterone, and testosterone on PrEP nucleotide concentrations in rectal and peripheral blood mononuclear cells. As well as the relationship between estradiol, progesterone, and testosterone on PrEP concentrations in plasma. Participants: Healthy, cisgender female, volunteers, aged 18-49 inclusive on the date of screening with an intact gastrointestinal system and regular menstrual cycle. Procedures (methods): Participants will take a single daily dose of study drug for five days before each sampling visit. The visits will be scheduled during the early follicular phase of the menstrual cycle (approximately days 2-5 after the first day of menses, Visit 1) when estradiol is predicted to be the lowest and the late follicular phase (approximately days 12-15 after the first day of menses, Visit 2) when estradiol is predicted to be highest. Samples of blood, rectal cells, and rectal tissue will be collected at both Visits 1 and 2. All participants will complete a follow-up safety visit within 14 days of completing study sampling.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS
CountriesUnited States

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 17, 2019
Enrollment StartMar 26, 2019
Primary CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.2 years ago

Interventions

Tenofovir 300Mg Oral Tabletdrug

Once daily dose of the combo tab x 5 days pre-sampling

Emtricitabine 200 MGdrug

Once daily dose of the combo tab x 5 days pre-sampling